Hair depigmentation and vitiligo-like lesions in a leukaemic paediatric patient during chemotherapy with dasatinib

Acta Dermato-Venereologica

Volumn 92, Issue 2, 2012, Pages 218-219

  Brazzelli, Valeria ^a   Grasso, Vincenzo ^a   Barbaccia, Vincenzo ^a   Manna, Giambattista ^a   Rivetti, Nicolò ^a   Zecca, Marco ^a   Giorgiani, Giovanna ^a   Vassallo, Camilla ^a   Borroni, Giovanni ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DASATINIB;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; CASE REPORT; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CYTOFLUOROMETRY; CYTOGENETICS; HAIR DEPIGMENTATION; HAIR DISEASE; HUMAN; IMMUNOPHENOTYPING; LETTER; LEUKOCYTOSIS; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA; VITILIGO;

ADOLESCENT; DRUG ERUPTIONS; HAIR DISEASES; HUMANS; HYPOPIGMENTATION; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; VITILIGO;

EID: 84859622548     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-1289     Document Type: Letter

References (15)

1. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988; 319: 990-998.
2. Wei G, Raflyath S, Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol 2010; 26; 3: 47.
3. Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2011; 117: 1800-1811.
4. Lindauer M, Hochhaus A. Dasatinib. Recent Results Cancer Res 2010; 184: 83-102.
5. Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007; 29: 2289-2308.
6. Shayani S. Dasatinib, a multikinase inhibitor: therapy, safety, and appropiate management of adverse events. Ther Drug Monit 2010; 32: 680-687.
7. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009; 10: 470-481.
8. Italian Association of Pediatric Hematology/Oncology, www.aieop.org. [cited 2010] Available at: https://www. aeiop.org/stdoc/lla/lla2000.doc.
9. Italian Association of Pediatric Hematology/Oncology, www.aieop.org. [cited 2010] Available at: https://www. aeiop.org/stdoc/proto/aieop_lla_rec_2003.pdf.
10. Aguilera DG, Tsimberidou AM. Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag 2009; 5: 281-289.
11. de Masson A, Bouvresse S, Clérici T, Mahé E, Saïag P. Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib. Ann Dermatol Venereol 2011; 138: 135-139.
12. Sun A, Akin RS, Cobos E, Smith J. Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor. J Drugs Dermatol 2009; 8: 395-398.
13. Wehrle-Haller B. The role of Kit-ligand in melanocyte development and epidermal homeostasis. Pigment Cell Res 2003; 16: 287-296.
14. Grichnik JM, Burch JA, Burchette J, Shea CR. The SCFKIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 1998; 111: 233-238.
15. Yoshida H, Kunisada T, Grimm T, Nishimura EK, Nishioka E, Nishikawa SI. Review: melanocyte migration and survival controlled by SCF/c-kit expression. J Investig Dermatol Symp Proc 2001; 6: 1-5.